Baillie Gifford acquired 15.6M Dexcom shares worth $1.13B. That's 0.92% of their equity portfolio (22nd largest holding). The investor owns 3.98% of the outstanding Dexcom stock. The first Dexcom trade was made in Q1 2013. Since then Baillie Gifford bought shares seventeen more times and sold shares on 34 occasions. The stake costed the investor $587M, netting the investor a gain of 93% so far.